1 Mizrahi, J. D., Surana, R., Valle, J. W. & Shroff, R. T. Pancreatic cancer. Lancet395, 2008-2020, doi:10.1016/S0140-6736(20)30974-0 (2020).
2 Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA: a cancer journal for clinicians70, 7-30, doi:10.3322/caac.21590 (2020).
3 Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer research74, 2913-2921, doi:10.1158/0008-5472.CAN-14-0155 (2014).
4 Allgower, C. et al. Friend or Foe: S100 Proteins in Cancer. Cancers12, doi:10.3390/cancers12082037 (2020).
5 Liu, Y. et al. Prognostic Roles of mRNA Expression of S100 in Non-Small-Cell Lung Cancer. BioMed research international2018, 9815806, doi:10.1155/2018/9815806 (2018).
6 Yang, X. Y. et al. Expression and clinical significance profile analysis of S100 family members in human acute myeloid leukemia. European review for medical and pharmacological sciences24, 7324-7334, doi:10.26355/eurrev_202007_21896 (2020).
7 Xiong, T. F., Pan, F. Q. & Li, D. Expression and clinical significance of S100 family genes in patients with melanoma. Melanoma research29, 23-29, doi:10.1097/CMR.0000000000000512 (2019).
8 Bai, Y., Li, L. D., Li, J. & Lu, X. Prognostic values of S100 family members in ovarian cancer patients. BMC cancer18, 1256, doi:10.1186/s12885-018-5170-3 (2018).
9 Ma, N., Zhu, L., Yang, L., Cui, Y. & Zhan, Y. Prognostic values of S100 family mRNA expression in ovarian cancer. Cancer biomarkers : section A of Disease markers25, 67-78, doi:10.3233/CBM-182276 (2019).
10 Zhang, S. et al. Distinct prognostic values of S100 mRNA expression in breast cancer. Scientific reports7, 39786, doi:10.1038/srep39786 (2017).
11 Huang, S. et al. Impact of S100A4 Expression on Clinicopathological Characteristics and Prognosis in Pancreatic Cancer: A Meta-Analysis. Disease markers2016, 8137378, doi:10.1155/2016/8137378 (2016).
12 Tsukamoto, N. et al. The expression of S100A4 in human pancreatic cancer is associated with invasion. Pancreas42, 1027-1033, doi:10.1097/MPA.0b013e31828804e7 (2013).
13 Ohuchida, K. et al. Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis. The Journal of pathology213, 275-282, doi:10.1002/path.2250 (2007).
14 Biankin, A. V. et al. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology137, 558-568, 568 e551-511, doi:10.1053/j.gastro.2009.04.009 (2009).
15 Vimalachandran, D. et al. High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer research65, 3218-3225, doi:10.1158/0008-5472.CAN-04-4311 (2005).
16 Xiao, M. B. et al. High expression of S100A11 in pancreatic adenocarcinoma is an unfavorable prognostic marker. Medical oncology29, 1886-1891, doi:10.1007/s12032-011-0058-y (2012).
17 Sealfon, S. C. & Chu, T. T. RNA and DNA microarrays. Methods in molecular biology671, 3-34, doi:10.1007/978-1-59745-551-0_1 (2011).
18 Rhodes, D. R. et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia9, 166-180, doi:10.1593/neo.07112 (2007).
19 Tang, Z., Kang, B., Li, C., Chen, T. & Zhang, Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic acids research47, W556-W560, doi:10.1093/nar/gkz430 (2019).
20 Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. Nature490, 61-70, doi:10.1038/nature11412 (2012).
21 Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling6, pl1, doi:10.1126/scisignal.2004088 (2013).
22 Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery2, 401-404, doi:10.1158/2159-8290.CD-12-0095 (2012).
23 Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nature communications10, 1523, doi:10.1038/s41467-019-09234-6 (2019).
24 Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic acids research47, D607-D613, doi:10.1093/nar/gky1131 (2019).
25 Li, T. et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer research77, e108-e110, doi:10.1158/0008-5472.CAN-17-0307 (2017).
26 Li, B. et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome biology17, 174, doi:10.1186/s13059-016-1028-7 (2016).
27 Andrew V, B. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology2 (2009).
28 Bachet, J. B. et al. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. European journal of cancer49, 2643-2653, doi:10.1016/j.ejca.2013.04.017 (2013).
29 Wen, Q., Zhao, Y. P., Chen, G., Zhang, F. Q. & Zhang, T. P. [Expression of S100A2 in secondarily radioresistant pancreatic cancer cells and significance thereof]. Zhonghua yi xue za zhi86, 2817-2820 (2006).
30 Wang, C. et al. Distinct prognostic roles of S100 mRNA expression in gastric cancer. Pathology, research and practice215, 127-136, doi:10.1016/j.prp.2018.10.034 (2019).
31 Zeng, M. L. et al. An Integrated Bioinformatic Analysis of the S100 Gene Family for the Prognosis of Colorectal Cancer. BioMed research international2020, 4746929, doi:10.1155/2020/4746929 (2020).
32 Bydoun, M. et al. S100A10, a novel biomarker in pancreatic ductal adenocarcinoma. Molecular oncology12, 1895-1916, doi:10.1002/1878-0261.12356 (2018).
33 Ohuchida, K. et al. S100A11, a putative tumor suppressor gene, is overexpressed in pancreatic carcinogenesis. Clinical cancer research : an official journal of the American Association for Cancer Research12, 5417-5422, doi:10.1158/1078-0432.CCR-06-0222 (2006).
34 Xiao, M. et al. S100A11 promotes human pancreatic cancer PANC-1 cell proliferation and is involved in the PI3K/AKT signaling pathway. Oncology letters15, 175-182, doi:10.3892/ol.2017.7295 (2018).
35 Mitsui, Y. et al. Upregulation of Mobility in Pancreatic Cancer Cells by Secreted S100A11 Through Activation of Surrounding Fibroblasts. Oncology research27, 945-956, doi:10.3727/096504019X15555408784978 (2019).
36 Takamatsu, H. et al. Extracellular S100A11 Plays a Critical Role in Spread of the Fibroblast Population in Pancreatic Cancers. Oncology research27, 713-727, doi:10.3727/096504018X15433161908259 (2019).
37 Zhu, H. et al. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer. Pancreatology : official journal of the International Association of Pancreatology21, 589-598, doi:10.1016/j.pan.2021.01.011 (2021).
38 Tu, G. et al. Expressional and Prognostic Value of S100A16 in Pancreatic Cancer Via Integrated Bioinformatics Analyses. Frontiers in cell and developmental biology9, 645641, doi:10.3389/fcell.2021.645641 (2021).
39 Fang, D. et al. S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways. Cell biology and toxicology, doi:10.1007/s10565-020-09574-w (2021).
40 Li, T. et al. S100A16 induces epithelial-mesenchymal transition in human PDAC cells and is a new therapeutic target for pancreatic cancer treatment that synergizes with gemcitabine. Biochemical pharmacology, 114396, doi:10.1016/j.bcp.2020.114396 (2020).
41 Ino, Y. et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. British journal of cancer108, 914-923, doi:10.1038/bjc.2013.32 (2013).
42 Jang, J. E. et al. Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer. Cell reports20, 558-571, doi:10.1016/j.celrep.2017.06.062 (2017).
43 Di Caro, G. et al. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut65, 1710-1720, doi:10.1136/gutjnl-2015-309193 (2016).